Patient safety and optimal performance:

Similar documents
MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)

WRHA Supply Chain New Technology Workshop Supply Chain Forum November 17, 2010

CADTH HEALTH TECHNOLOGY MANAGEMENT PROGRAM Horizon Scanning Products and Services Processes

A Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data

Advancing Health and Prosperity. A Brief to the Advisory Panel on Healthcare Innovation

Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA

Alberta Health Services and Advancing Uptake of HTA & Innovation

The Potential Social and Economic Value of Innovation Procurement

Issues in Emerging Health Technologies Bulletin Process

SURGERY STRATEGIC CLINICAL NETWORK EVIDENCE DECISION SUPPORT PROGRAM. New ideas & Improvements

Centre for the Advancement of Health Innovations (CAHI)

Reduce cost sharing and fees Include other services. Services: which services are covered? Population: who is covered?

Quality assurance in the supply chain for pharmaceuticals from the WHO perspective

Changing landscape - changing paradigms

Reflection Paper on synergies between regulatory and HTA issues. DG SANTE Unit B4 Medical products: safety, quality, innovation

IP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE?

Health Technology Assessment (HTA): A Primer for Procurement Professionals

Overview of Health Technology Assessment (HTA) from Asia Pacific Perspective

WHO Regulatory Systems Strengthening Program

Regulatory Science For Innovation

December Eucomed HTA Position Paper UK support from ABHI

Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities

Transforming How We Manage Health Technologies in Support of Better Health, Better Patient Experience, and Better Value

SPC Spring Meeting March 21, 2013

Health Technology Assessment and the European Network for HTA

Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum

This document is a preview generated by EVS

What We Heard Report Inspection Modernization: The Case for Change Consultation from June 1 to July 31, 2012

Use of the Graded Approach in Regulation

Health Innovations in Horizon 2020: the framework programme for research and innovation ( )

Finn Børlum Kristensen, MD, PhD Director, EUnetHTA Secretariat Danish Health and Medicines Authority (EUnetHTA Coordinator) Copenhagen, Denmark

Building quality into HTA and Coverage Decision- Making Processes: What are the features of good practice in HTA?

Zayna Khayat, PhD., MaRS, Canada

Strategies for Knowledge Translation and Mobilization to Inform Hospital Health Technology Use

HTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:

Exploring Canada s early scientific advice: Global and Canadian context, CADTH and Health Canada perspectives. October 18, 2017

EDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE : 20 YEARS OF EXPERIENCE March EDQM, Strasbourg, France ABSTRACTS

Digital Identity Innovation Canada s Opportunity to Lead the World. Digital ID and Authentication Council of Canada Pre-Budget Submission

Can. meet the. medicine? Healthcare SMEs. challenges of 4P.

Available online at ScienceDirect. Procedia Manufacturing 3 (2015 )

Adaptation of HTA reports: an effective way to use limited resources?

Draft Plan of Action Chair's Text Status 3 May 2008

Health Technology Assessment: What are the key challenges to assess medical devices? Rosanna Tarricone, PhD Director CERGAS Scientific Director EHTI

The Canada Foundation for Innovation: assessing the impact of funded research infrastructure

SHTG primary submission process

National Coordinated Registry Network (CRN) Think-tank

Medical Device Industry in India

Canada s Research-Based Pharmaceutical Companies (Rx&D) 2015 Pre-Budget Submission House of Commons Standing Committee on Finance.

Medical Device Usability Engineering. Product and Service Design Innovation Consultancy

Intellectual Property

Brief to the. Senate Standing Committee on Social Affairs, Science and Technology. Dr. Eliot A. Phillipson President and CEO

A manifesto for global sustainable health. Sustainable Health Symposium Cambridge, UK 25th July 2017

The CNSC s Approach to Communications

13 December A NERA Briefing: Expert Workshop on HTA Workshop Sponsored by Pfizer

Protection of Privacy Policy

ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective

Compliance for Eucomed: The Medical Technology Industry s s Perspective

Supporting Innovation through Regulation and Science

EXPLORATION DEVELOPMENT OPERATION CLOSURE

Water, Energy and Environment in the scope of the Circular Economy

E Distr. LIMITED E/ESCWA/TDD/2017/IG.1/6 31 January 2017 ENGLISH ORIGINAL: ARABIC

Maturity Model for Integrated Care Dr Andrea Pavlickova NHS 24, Scotland

ABHI Response to the Kennedy short study on Valuing Innovation

Medical Technology Association of NZ. Proposed European Union/New Zealand Free Trade Agreement. Submission to Ministry of Foreign Affairs & Trade

Final Document. Title: The GHTF Regulatory Model. Authoring Group: Ad Hoc GHTF SC Regulatory Model Working Group

Health & Social Care Industrial Innovation

Dr Andrea Pavlickova NHS 24, Scotland

European Network for Health Technology Assessment (EUnetHTA) Joint Action 3

clarification to bring legal certainty to these issues have been voiced in various position papers and statements.

'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint

EU s Innovative Medical Technology and EMA s Measures

National Incident Management System

Swissmedic, Swiss Agency for Therapeutic Products

PUBLIC ART PLAN FOR THE NEW PATIENT TOWER, ETOBICOKE GENERAL HOSPITAL CAMPUS 101 HUMBER COLLEGE BLVD. TORONTO ONTARIO

The EFPIA Perspective on the GDPR. Brendan Barnes, EFPIA 2 nd Nordic Real World Data Conference , Helsinki

Article 117 A Notified Body perspective, advice on how and when to engage notified bodies

Health Technology Strategy 1.0. June 2004

Implementing Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property in the Eastern Mediterranean Region

Scottish Health and Life Sciences Innovation Workshop. The Industrial Strategy Challenge Fund

The skilled collaborators - the winners in a digitized maritime sector

Safer Chemistry Research in Context

Comments from CEN CENELEC on COM(2010) 245 of 19 May 2010 on "A Digital Agenda for Europe"

BMET7102 MEDICAL DEVICE DEVELOPMENT AND STANDARDS

The Assessment of Benefits and Harms and Their Relative Importance for Patients, Industry and Agencies: How should they be captured?

USP Research & Innovation Program

This document is a preview generated by EVS

Strategic Foresight Initiative 2011 Summary Briefing

Knowledge Translation: Where Are We? and Where Do We Go From Here?

The Biological Weapons Convention and dual use life science research

FDA Centers of Excellence in Regulatory and Information Sciences

NCRIS Capability 5.7: Population Health and Clinical Data Linkage

COUNTRY: Questionnaire. Contact person: Name: Position: Address:

Standing Committee on the Law of Patents

Harmonization of Nuclear Codes & Standards Pacific Nuclear Council Working and Task Group Report

25 th Workshop of the EURORDIS Round Table of Companies (ERTC)

EU regulatory system for robots

Progress in FDA s Drug Product Quality Initiative. Janet Woodcock, M.D. November 13, 2003

New methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients?

By Justin Dill, Jacob Lindamood, David Stauffer, Mihai Prisacariu, and Jamie Zikos

Complementi di Informatica Medica a.a JunHua Li and Pradeep Ray - University of New South Wales, Sydney, Australia

Transcription:

Patient safety and optimal performance: a holistic framework for medical devices Michael Cheng Independent Patient Safety Advocate cheng12@sympatico.ca Canadian Agency for Drugs and Technologies in Health Symposium 2014

WHO publication (Ref. 1) available on the Internet

Key points focus: regulated products; users =professionals, patients and public differences between medical devices and drugs 3 essential steps to ensure device patient safety 3-stage framework for optimal performance reflecting World Health Assembly Resolution WHA 60.29 3-stage framework as simple reference to facilitate education and communication among stakeholders design and functioning of complex holistic system for best outcome

Medical Devices and Drugs The Twin with Different Nature Medical devices Drugs User interface Device-user-patient Drug-patient Effecting Outcome User knowledge and skills Active ingredients ***** Maintenance Essential Nominal Facility Planning Technical support Recurrent Operation Budget Critical Essential for durable devices Minimal Nominal

Three essential steps to ensure medical device patient safety Step 1 Government Product Safety Assessment (medical device regulation) (Health Canada medical device license for classes 2, 3 and 4) Step 2 User Contextual Safety Assessment Environmental Human factor etc Step 3 User Safe Use and Management User training Maintenance Performance surveillance

Provocative thoughts Majority of the public, including healthcare professionals, may not know the scope and limitation of medical device regulations; often they have unrealistic expectations of the regulators ability to protect their safety The Government could update the public perception of medical device safety and define user responsibilities

Three essential steps to ensure medical device patient safety Step 1 Government Product Safety Assessment (medical device regulation) (Health Canada medical device license for classes 2, 3 and 4) Step 2 User Contextual Safety Assessment Environmental Human factor etc Step 3 User Safe Use and Management Cultivate culture Informed acquisition Responsibility Accountability Overall Instructions for Use (user responsibility)

Global calls for rational use of medical technology To curb soaring global healthcare cost, in 2007, World Health Assembly Resolution (WHA 60.29) calls for rational use of medical technologies highlighting HTA The 3-step diagram can be enriched to guide national or individual policies in safe and optimal utilization of medical devices in line with WHA 60.29

Handy Policy Framework for Optimal Utilization of Medical Devices 1. Device Market Regulation General assessment with globally harmonized criteria Good Manufacturing Practices 2. Adoption / Selection Focused assessment with user needs and contexts (health policy, safety costs...hta etc.) 3. Utilization / Disposal Safe effective use Performance surveillance Good Planning and Management Practices policy equally applicable at national or individual levels

holistic system needs collaboration for best outcome 1. Device Market Regulation General assessment with globally harmonized criteria Good Manufacturing Practices 2. Adoption / Selection Focused assessment with user needs and contexts (health policy, safety costs..hta.etc.) 3. Utilization / Disposal Safe effective use Performance surveillance Good Planning and Management Practices interaction and collaboration needed

Stakeholders for Medical Devices (WHO Ref 1, Figure 3, Page 8)

active ingredients for medical devices? by linking the isolated stakeholders to collaborate

Active ingredients for medical devices Manufacturer Vendor Government active COLLABORATION User Public/ Patient

some suggestions Health Canada could explicitly disclose limitation of the device regulations and define user responsibilities Government and industry could encourage informed medical device users and empower them with evidence-based benefits and risk information CADTH could consider including user contextualized environmental and human factors in assessing device safety in HTA projects involving medical devices The public should encourage active collaboration among all stakeholders on the holistic system design and operation for best outcome

References 1. WHO: Medical Device Regulations: Global Overview and Guiding Principles Chapter 2, 2003 www.who.int/medical_devices/publications/en/md_regulations.pdf 2. Cheng, M: Share responsibility in medical device safety and performance September/October 2010, p. 10-11, Regulatory Affairs Medtech Journal www.regulatoryaffairsmedtech.com 3. Andrea Cassino-Piché et al: Choosing safer medical technology: using human factors methods in the procurement process P49-56, Human Factor Horizons 2010 4. WHO: The World Health Assembly Resolution WHA60.29, 2007 http://www.who.int/medical_devices/resolution_wha60_29-en1.pdf 5. World Bank: An Overview of Medical Device Policy and Regulation, HPN Brief #8, 2007 http://siteresources.worldbank.org/healthnutritionandpopulation/resour ces/281627-1109774792596/hnpbrief8.pdf